Solara Active Pharma Sciences Limited reported its Q4 FY25 performance with revenues of INR 2,790 million and an EBITDA of INR 510 million, reflecting a significant increase in gross margin and EBITDA despite a challenging year.
AI Assistant
Solara Active Pharma Sciences Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.